Transcript IDA Corporate Powerpoint template - Okinawa Institute of Science

sedb.com
Singapore's Experience - Economic Development with Science and Technology
6 October 2010
Innovator of
new products
& services
InnovationIntensive
Technology-intensive
2000+
1990s
Capital-intensive
1980s
Skills-intensive
Labour-intensive
1970s
1960s
2
Singapore’s Economy
GDP & Trade
2009 GDP (US$160 Billion)
2008 Trade
(US$660 Billion)
3
150,000
100,000
50,000
250,000
300,000
US$147 billion (2009)
SARS CRISIS
ASIA $ CRISIS
US$25 billion (1986)
200,000
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009 (p)
S$ mil
Total Manufacturing Output
(1986 – 2009)
0
4
Total Manufacturing Output of 4 key clusters :
US$115 billion (2009)
120,000
80,000
Electronics
60,000
Chemicals
40,000
Biomedical
Sciences
20,000
Precision Engrg
0
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009 (p)
S$ mil
100,000
Electronics
Chemicals
5
Building the Data Storage Industry Cluster
S$ mil
PHASE
GROWTH
PHASE
BUILD UP
PHASE
US$13
billion
(1997)
DECLINE
Cumulative Output (1986-2009): US$178 billion
US$5.5
billion
(2009)
US$1.6
billion
(1986)
6
Building the Semiconductor Industry Cluster
US$26.3 billion
(2009)
PHASE
GROWTH
PHASE
BUILD UP
Cumulative Output (1986-2009): US$247 billion
S$ mil
US$7.6 billion
(1998)
US$1.6 billion
(1986)
7
Building the Precision Engineering Industry Cluster
Cumulative Output (1986-2009): US$221 billion
18,000
US$ 17billion
(2008)
US Million
12,000
10,000
PHASE
BUILD UP
14,000
PHASE
US$7 billion
(1993)
GROWTH
16,000
8,000
6,000
US$2.6
billion
(1986)
4,000
2,000
8
Building The Chemicals Industry Cluster
Cumulative Output (1986 – 2009) - US$505 billion
120000
S$ mil
100000
1995
Construction
started on Jurong
Island
(US$12
billion)
80000
US$40 billion
(2009)
Official Opening
of Jurong Island
(US$22 billion)
60000
40000
20000
0
1986
1988
1990
1992
1994
1996
1998
2000
2002
2004
2006
2008
9
•Jurong Island:
•Heart of Singapore’s Chemicals Hub
•S$ 7 billion Reclamation Project
•Singapore
•S$38b of investments
•99 companies
•Over 15,000 employees
10
Building The Biomedical Sciences Industry
Cluster
S$ mil
20,000
15,000
PHASE
BUILD UP AND
25,000
US$14.7 billion
(2009)
GROWTH
30,000
Cumulative Output (1986 – 2009) - US$120 billion
US$4 billion
(2000)
10,000
5,000
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009 (p)
0
Manufacturing Output
Value Added
11
Tuas Biomedical Manufacturing Park
12
Building up Biomedical Sciences
2001
A*STAR
13
Vision
Singapore – The Biopolis of Asia
An International Biomedical Sciences Cluster Advancing Human Health
Through the Pursuit of Excellence in
Research & Development, Manufacturing, and Healthcare Delivery
Basic,
Translational
& Clinical
Research
Product &
Process
Development
Pilot &
Commercial
Manufacturing
Regional HQ &
Shared
Services
Healthcare
Delivery
14
•How It All Started….
•Prof. John Wong
•A/Prof. Kong Hwai Loong
•Prof. Tan Chorh Chuan
15
One North - Bird’s Eye View
16
© 2010 IDA Singapore. All Rights Reserved.
CONFIDENTIAL
‹#›
Research Institutes
Biopolis
Biopolis
Fusionopolis
Phase I
Phase II
Phase I
(2003)
(2006)
(2008)
•Biological
Resource
Centre
(BRC) 2005
•Institute of High
Performance
Computing (IHPC)
1998
•Biopolis
•Institute of
Materials
Research &
Engineering
(IMRE) 1996
•Institute of
Molecular &
•Cell Biology
(IMCB) 1987
Bioinformatics
•Institute (BII)
2001
•Data Storage
•Institute for
1992
Institute of
Manufacturing
Technology
(SIMTech) 1985
•Institute of
•Genome
Microelectronics
(IME) 1991
•Institute of
•1987-
•1990-
1989
1999
•Bioprocessing
Infocomm Research •Technology
•Institute (BTI) 2003
(I2R) 2002
•Institute (DSI)
•Singapore
Shared
Facilities
(BSF)
2005
•Institute for
Chemical &
•Singapore Engineering
(GIS) 2000
Sciences (ICES)
2002
•Singapore
Consortium for
Cohort Studies
(SCSC) 2006
•Singapore
Bioimaging
Consortium
(SBIC) 2005
Metrology
Centre (NMC)
•Singapore
2008
•Institute for
•Experimental
Clinical
Sciences (SICS)
2006
Therapeutics
Centre (ETC)
•Institute of
•Singapore
•Bioengineering &
Stem Cell
•Singapore
Consortium Immunology
(SSCC) 2006 Network (SIgN)
• 2006
Nanotechnology
(IBN) 2003
•National
•2008
•Institute of
Medical
•Biology (IMB)
2007
•200
•2001
•2003
•2005
•2007
0
-2002
-2004
-2006
-2008
•A*STAR has more than 2,300 RSEs, of which more than 50% of them are
international talent from some 50 countries – 60% PhD
18
Driving Basic Research towards Clinical Outcomes
•CLINICAL
• RESEARCH
•MEDICAL
PHARMACEUTICALS
•TECHNOLOGY
•Bioprocessing
•Chemical Synthesis
•Genomics & Proteomics
•Industry
•Industry
•Molecular & Cell Biology
Sectors
•Bioengineering &
Sectors
•Nanotechnology
•Computational
•Biology
HEALTHCARE
•Immunology
BIOTECHNOLGY
SERVICES &
& BIOLOGICS
DELIVERY
•TRANSLATIONAL
RESEARCH
19
Co-investment, VC funding
RISC grants, infrastructure, tax
breaks
INDUSTRY
Pharma
MTI
MEaT
Drug discovery & devt
Med tech / devices
Biologics (cells / vaccines)
Biotech
Overseas
Clinical
Trials
Clinical Trials
Singapore
Clinical Trials
MOH
Mission-oriented BENCH
Research Institutes
• IMCB, GIS, BTI
• IBN, BII,
• IMB
Research Consortia
• SBIC • SIgN
• SSCC • Biomarkers
Academic BENCH
NUS, NTU
Translational /
Investigational
Medicine
A*STAR / BMRC
SICS
STN
SCS
DPF Office
SCCS
MBBS PhD / BMS IF /
CSI awards
BEDSIDE
NMRC / HSA
Clinical Research Programmes
• Focus, strategy
Human Capital
• Development, recruitment
Infrastructure
• For Clinical Trials
Regulatory Framework
• IRBs
MEaT = Medical Enginering and Technology
IMCB = Institute of Molecular & Cell Biology
GIS = Genome Institute of Singapore
BTI = Bioprocessing Technical Institute
IBN = Institute of Bioengineering and Nanotechnology
BII = Bioinformatics Institute
IMB = Institute of Medical Biology
SICS = Singapore Institute for Clinical Sciences
SBIC = Singapore Bioimaging Consortium
SIgN = Singapore Immunology Network
SSCC = Singapore Stem Cell Consortium
STN = Singapore Tissue Network
SCS = Singapore Cancer Syndicate
SCCS = Singapore Consortium of Cohort Studies
DPF
= Data Privacy Framework
BMS IF = Biomedical International Fellowship
CSI
= Clincian Scientist Investigatorship
20
IRBs = Institutional Review Boards
Portfolio approach to creating economic value
•START-UPs based on new tools, reagents, assays etc.
•Life Science
Tools – New
Applications
Devt
•Novel
Techniques
• Spun out from IBN
• Spun out from SIgN
• Identified as one of industry's
• Predicts and optimize peptide
most innovative emerging
laboratory technologies1
•New manufacturing R&D centres/pilot
plants/facility e.g.
•Novel Mfg
•Public
Technology
Sector
R&D
vaccines, reducing cycle
development time
•PharmBio
Mfg
Technologies
•GSK Green Manufacturing endowment fund
•taps onto R&D expertise in BTI, IBN, NUS,
•NTU, ICES
•Private public partnerships e.g.
•Novel
•Novel
•Biomarker &
Technology
Platforms
compound
•‘Niche’
Research
Organizations
•21
•R&D
collaborations
institutions (see next slide).
•Service providers based on technology platforms
developed, fill industry’s in-house capability gaps
e.g.
•1LabAutomation's prestigious
Innovation AveNEW
•Roche’s partnership with Singapore
•Clinical Imaging Research Centre: NUS-
A*STAR joint partnership with Siemens
21
Collaboration with Industry model
•Roche Hub for Translational Medicine in Singapore
•“Singapore Inc” R&D consortium (among public sector R&D players)
Basic
Preclinical
Research
Clinical
Research
Translational
Research
Research
> Roche’s 1st Hub for
Translational Medicine (TM)
worldwide
> Single Master Collaboration
Roche
> Investment of 100mil Swiss
Francs
Hub for
Translational
> Focus on expanding disease
biology understanding to
develop new personalised
treatment approaches
Medicine
Agreement with Singapore Inc.
entities, including A*STAR, NUS,
NTU, NUH, NHG, SingHealth
> Joint Steering Committee between
Roche & Singapore institutes to
define strategic direction & oversee
research projects
•Biomedical Research Council
22
Fusionopolis Phase 1 Facilities
Serviced Work-Live
Apartments
Fitness Gym & Pool
Skybridges and Sky
Gardens
Business and
Research Space
Shared
Conference Rooms
500-seat
Experimental
Performance
Theatre
Retail and F&B
Podium
one-north MRT Station
23
•Science and Engineering Research Council (SERC)
To capture economic value
through the exploitation of intellectual & human capital derived from basic &
applied research
Blue-sky
Basic (directed)
Applied
Commercialization
Leverage
Push out
Extramural Programs
Support thematic
capabilities
● Leverage on
external expertise
●
Focus
●
●
●
Medium to long term industryoriented R&D
Build, strengthen and anchor
industrial R&D capability
Develop Human, Intellectual,
Industrial Capital
•Confidential – Not for Circulation
Industry Engagement
●
●
Research collaboration
with MNCs and SMEs
Technology Licensing
24
Science and Engineering Research Council
•INFOCOMM
ELECTRONICS
Advanced Display
Electronic Components
IME
DSI
Data
•ELECTRONICS
Electronic Modules
Communications
Software & Computing
Storage
Semiconductors
Storage & Peripherals
I2R
Digital Content & Media
Microelectronics
Devices
Info-Comm Sciences
Computational Sciences
•Industry
Sectors
•Industry
Materials Sciences
Sectors
Chemical Sciences
Specialty Chemicals
Manufacturing
Precision Components
Technology
Precision Modules
Performance Materials
CHEMICALS
•
Bio & Consumer
Chemistry
Process Engineering *
Machinery & Systems
Metrology
Petroleum/Petrochemicals
Aerospace
IMRE
ICES
CHEMICALS
SIMTech
IHPC
Marine & Offshore
Automotive
ENGINEERING *
•Alignment of SERC RIs to meet Industry Needs
•History | KBE | Biomed | S&E | Talent |
25
Developing New Competencies
ELECTRONICS
INFOCOMM
Imaging
Advanced Display
Nano-elect.
Polymer Elec.
Photonics
Communications
Electronic
Components
Data
Storage
MicroElectronics
Electronic Modules
Semiconductors
Storage &
Peripherals
Info-Comm Sciences
Software &
Computing
Digital Content &
Media
Devices
Computational Sciences
Ultra wide
Band
Home
2015
Materials Sciences
Chemical Sciences
Nanotechnology
Manufacturing Technology
Human-factor
Engineering
Metrology
Human-machine interface
Specialty Chemicals
Arrayed sensor networks
Performance Materials
Precision
Sensors
Aerospace
Mfg
Systems
Machinery &
Modules
Systems
Petroleum/Petrochemicals
Bio & Consumer
Chemistry
Process Engineering
Precision
Components
Synthetic
Chemistry
Offshore
Engrg
ENGINEERING
CHEMICALS
Energy
26
Human Capital –
Catch a few Whales !
27
Attracting International
Scientific Talent
•Dr Sydney Brenner
•Dr David
•Prof Charles
Srolovitz
Zukoski
Scientific Adviser,
•Exec Dir, IHPC •Chmn, SERC
A*STAR
•Prof Dim-Lee
Kwong
Exec Dir, IME
•Dr Edison Liu
Exec Dir, GIS
•Dr Keith
Carpenter
•Exec Dir, ICES
•Dr Jackie Ying
•Exec Dir, IBN
•Sir George Radda
•Dr Edward Holmes
Chmn, BMRC
•Executive Dy Chmn
(TCSG), BMRC &
•Chmn, NMRC
•Exec Dir, DSI
•Castagnoli
•Swain
•Scientific Dir,
•Exec Dir, SICS
•Exec Dir, SSCC
•Dr Dale Purves
•Exec Dir, NRP
•SIgN
•Sir David Lane
•Dr Birgitte Lane
•Dr Frank
Eisenhaber
•Dr Alex Matter
•Dy Dir, IMCB
•Chief Scientist
Exec Dir, IMB
•Director, BII
•Director, ETC
•Prof Stephen Quake
•Consultant
•Prof Paola
•Dr Judith
•Dr Alan Colman
•Dr Phil Ingham
•Dr Pantelis
Alexopoulis,
•Dr Philippe
Kourilsky
Chairman, SIgN
•Dr Jean Paul
•Thiery
•Dy Dir, IMCB
•Prof Peter
Gluckman
PI, SICS
•Dr Davor Solter
PI, IMB
•Prof David
•Townsend
•Dr Stephen
Cohen
Acting
Exec
Head of PET and SPECT
Dir, IMCB
Group, SBIC
28
Attracting and Growing R&D
Partnering with Industry
29
Human Capital –
Train 1,000 PhD Guppies
Guppy – 0.03 meters
30
Nurturing & Developing Human Capital
(Guppies)
Evelyn Thangaraj
2005 A*STAR
YRAP Scholar
(currently A*STAR
NSS BS Scholar)

10-14 yrs
Youth
Science
15-18 yrs
19-23 yrs
YRAP &
NSS(BS)
A*STAR Science
PGS
Awards
Young
Whales
Guppies
Le Ngoc Phuong
Lan
2005 A*STAR YRAP
Scholar
(currently A*STAR
NSS BS Scholar)
Senior
Guppies
Talent Pipeline

24-30 yrs
NSS(PhD)
AGS
SINGA
< 35 yrs
AIF
AGS (Post-doc)
31
•Human Capital: International Guppies
•MIT
Physics
•Stanford
•MIT
•Chemical Engineering
•Bio Engineering
•(Malaysia)
•(Shanghai)
•(Hong Kong)
•Stanford
•MIT
•Computer Science
•Chemical Engineering
32
Human Capital: Singapore Guppies
Stanford
Comput
er
Science,
PhD
Stanford
Developmental
Biology
PhD
Cambridge
Natural Science
Biology
BSc
Carnegi
e Mellon
Comput
er
Science,
BSc
Cambridge, London
Medicine/PhD
Stanford
Genetics
PhD
Imperial College London
Cancer Biology
PhD
NUS
Biomedical
Sciences
PhD
NTU
Biological
Sciences
BSc
Harvard
Stem cells
Post-Doc
33
2009 Recession
Action Taken

Immediate Responses to Overcome Crisis




First-ever Use of National Reserves (S$)
Saving Jobs
Enhancing Credit to Businesses
Build for the Future

Business Upgrading Initiative for Long-term
Development Package to upgrade enterprise
capabilities
 Economic Strategies Committee (ESC) to chart future
path for the economy
34
Objective & Structure of Economic Strategies
Committee (ESC)
Objective of ESC: Growing Singapore’s future
STRONG CAPABILITIES
HIGH PRODUCTIVITY
SUSTAINED AND INCLUSIVE GROWTH
as a leading global city in the heart of Asia and ASEAN
1. Seizing Growth Opportunities
2. Developing A
Vibrant SME Sector
& Globally Competitive
Local Companies
7. Ensuring Energy
Resilience and
Sustainable Growth
4. Growing
Knowledge Capital
Corporate
Resilience
& Depth
3. Attracting and
Rooting MNCs &
foreign SMEs
8. Maximising
Value from Land
as a Scarce
Resource
Resource
Optimisation
Human &
Knowledge
Capital
5. Making
Singapore a leading
Global City
6. Fostering Inclusive Growth
35
Key Development Strategies
36
Singapore’s Economic Strategies Committee
•Vibrant Centre for knowledge creation, innovation and
commercialisation for higher productivity-based growth
(1) Sustaining Knowledge
Creation
•
Research
Performers
•Public
(2) Growing Innovation Capital
Innovation Capital
Integrating for Impact
e.g. one-to-one collaborations, consortia,
system-level integration
•e.g. A*STAR RIs
•IHLs
•e.g. Universities, RCEs,
CREATE, Duke-NUS GMS
Enterprises
MNC/
GCC
Gearing for Growth
•Local
e.g. teaming local enterprises up with MNCs through
consortia, COI, outreach activities
Enterprise
•Hospitals
•e.g. Singhealth, NHG
•Corp Labs
Seeding for Surprises
e.g. encouraging entrepreneurship, use-driven
platforms, commercialising IP
Start-up
(3) Attracting and Developing Talent in RIE
(4) Funding (GERD - 3.5% of GDP by 2015)
37
Government’s Commitment to R&D
•R&D Spending as % of GDP
4.0%
•Target of 3.5% GERD/GDP by 2015
3.5%
•Current target: to reach 3% GERD/GDP
2.8% by 2010
3.0%
2.5%
2.5%
2.1%
2.2%
2.1%
2.2%
•2.8%
2.3% 2.3%
1.9%
2.0%
1.5%
1.0%
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Gross Expenditure on R&D (GERD) / GDP
5-year
•Source: R&D Survey 2000-2008
Science & Technology Plan
National
National
Science &
Science &
Technology
Science &
Technology
Technology
Plan
Technology Plan
Plan 2005
Plan 2010
(1991-1995)
(1996-2000)
(2001-2005)
2006-2010)
S$2 billion
S$4 billion
S$6 billion
S$13.9 billion
•Research, Innovation &
Enterprise 2015
•(2011-2015)
•S$ 16.1 billion
38
•Singapore Economy as a Dynamic Pyramid
●
Agency for Science, Technology & Research
●
- Generating Know-How
Global
Economic Development Board
- Attracting Foreign Direct Investments
& Large
- Attracting Whales
- Nurturing Guppies
Companies
●
●
●
~ 1,400
- $100m
IE Singapore
●
●
- Expanding
Small & Medium Enterprises
Overseas Market
●
~ 30,000
Access
●
- Nurturing and
Growing
- $1m
Enterprises
Micro-Enterprises
●
●
SPRING
~ 110,000
JTC – Industrial Land & Space
39
Seeding & Nurturing Innovative Start-ups
Key Initiatives
•Idea
•Proof of Concept/
•Go to
•Promising
•Generation
•Commercialisation
•Market
SMEs
Technology
YES! Schools
Enterprise
Total: 31 schools
supported, benefiting
Commercialisation
6,000 students
Scheme (TECS)
YES! Start-Ups
 Support Proof-of-Concept
 Total: 41 start-ups
 Total : 54 projects
 & Proof-of-Value projects
SPRING SEEDS
 Co-investment for
start-ups
 Total: 173 start-ups
Incubator Development Programme
 Total: 10 incubators & venture accelerators
40
•Access to Innovation & Technology
Innovation Voucher Scheme (IVS)
(launched Mar 09)
 Encourage SMEs to enhance or
develop new product / process
 To support projects or procure
services from the various approved
knowledge institutions
•Approved
Centres of
•Innovation:
41
•41
•Building Technology Infrastructure
Centres of Innovation (COIs)
One-stop centres offering technology consultancy and advice
Food Innovation & Resource
Centre @ S’pore Polytechnic
Centres
of
Innovation
(launched May 07)
Precision Engrg COI @
A*STAR SIMTECH
(launched May 08)
Electronics COI @
Nanyang Polytechnic
(launched on Jan 09)
Marine & Offshore Tech COI
@ Ngee Ann Polytechnic
(launched Oct 07)
Enviro & Water Tech COI
@ Ngee Ann Polytechnic
(launched Jul 08)
42
•42
•Catalysing Technology Start-ups
•Technology Enterprise
Commercialisation Scheme (TECS)
(launched Apr 2008)
 Support early-stage Proof-of-Concept (POC) and
Proof-of-Value (POV) projects
43
•43
•Upgrading Technology Innovation in SMEs
Technology Innovation Programme (TIP)
•Catalyse Technology Projects
 Promote technology awareness to SMEs in key
industries
 Facilitate & support technology projects by SMEs
TECHNOLOGY
INNOVATION
IN SMES
•Develop Technology
Infrastructure
•Build Technology
Innovation Capabilities
 Set up 5 Centres of Innovation
 Work with A*STAR’s T-Up
for key industry sectors
 Develop network of
technology resources
programme
 Second local / overseas experts
& talent to SMEs
 Set up technology talent
database
44
•44
•Seeding & Nurturing Innovative Start-ups
•Incubator Development Programme (IDP)
 5 incubators & 5 venture
accelerators supported
 To increase ISU’s access to
•
- Finance
•
- Overseas Markets
•
- Mentors & Experts
•
- Tech facilities
 Expected to nurture 330
startups over 3 years
NUS Enterprise Incubator
NTU NanoFrontier
iAxil Business Incubator
Parco Fashion Incubator
45
•45
•Building Enterprise Capabilities
•Intellectual Property Management Programme
•Phase I
Phase I
SCOPE IP™
•IPM Diagnostic tool to assess IP deployment and
IPM systems
•Provide strategic options and recommendations
Phase II
IPM
Capability
Development
Projects
•Phase II
•Implementation of recommendations eg:
 IP Audit
 IP Education and Training
 IP Intelligence and Research
 IP Portfolio Management
 IP Strategy
 IP Valuation
 IP Licensing
46
•46
Singapore’s Growth Forecast
•2009p
•Economic indicator
•(year-on-year change)
•2010
•Latest
• (%)
•Median
•forecast (%)
•Annual Growth Rate
•- 1.3
•14.9
• Manufacturing
•- 4.1
•28.7
•1.3
•10.6
•16.2
•10
• Wholesale & retail trade
•- 8.2
•15.9
• Hotels & restaurants
•- 1.5
•8.8
•Exports
•- 18
•19.5
•Inflation
•0.6
•2.9
•3
•2.2
• Financial Services
• Construction
•Unemployment rate
47